Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 13/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | TOP2A | P11388 | 1/20 | 0.47 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1142890 | 0.87 | NISCH (0.53) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL1143063 | 0.84 | NISCH (0.57) | NISCHLMNARECQLTOP2ATOP2B | |
| Hydrochloric Acid SCHEMBL6365863 | 0.83 | LMNA (0.56) | NISCHLMNARECQLTOP2ATOP2B | |
| Hydrochloric Acid SCHEMBL4949181 | 0.81 | LMNA (0.54) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL27983465 | 0.78 | IKBKB (0.50) | NISCH | |
| SCHEMBL13175784 | 0.78 | NISCH (0.60) | NISCHCYP3A4HSD17B10 | |
| SCHEMBL5476725 | 0.75 | NISCH (0.79) | NISCHHSD17B10LMNARECQLTOP2A | |
| SCHEMBL9082178 | 0.75 | CYP3A4 (0.46) | NISCHCYP3A4ALOX15HSD17B10 | |
| SCHEMBL5443690 | 0.75 | CHUK (0.55) | NISCH | |
| SCHEMBL9114689 | 0.75 | NISCH (0.57) | NISCHTOP2ATOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340505-B2 | Type III secretion inhibitors, analogs and uses thereof | UNIVERSITY OF MASSACHUSETTS (US) | 2016-05-17 | — | — | US | disclosed |
| US-20140323483-A1 | TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF | UNIVERSITY OF MASSACHUSETTS (US) | 2014-10-30 | — | — | US | disclosed |
| US-20110034463-A1 | TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-10 | — | — | US | disclosed |
| WO-2009145829-A1 | TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF | UNIVERSITY OF MASSACHUSETTS (US) | 2009-12-03 | — | — | WO | disclosed |
| WO-1996028443-A1 | THERAPEUTIC BENZOXAZOLES | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034463-A1 | TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF | GBA3, CLPP, PEX3 | NISCH 300/4885CYP3A4 3546/4885ALOX15 3540/4885 |
| US-20140323483-A1 | TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF | GBA3, CLPP, PEX3 | NISCH 300/4885CYP3A4 3546/4885ALOX15 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.